A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Reldesemtiv (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Acronyms FORTITUDE-ALS
- Sponsors Cytokinetics
- 15 Feb 2018 According to a Cytokinetics media release, results from this trial is anticipated in 2H 2018.
- 15 Feb 2018 According to a Cytokinetics media release, this trial has screened over 100 patients and enrolled nearly 90 patients toward the objective of 445 patients
- 30 Nov 2017 According to a Cytokinetics media release, the results from this trial is anticipated in 2018.